Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 596-600

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

APPENDIX CARCINOMA; BILE DUCT CARCINOMA; COLON CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METASTASIS; MIXED MULLERIAN TUMOR; NEOPLASM; OVARY TUMOR; PANCREAS CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CARCINOMA; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; TERATOMA; UPPER GASTROINTESTINAL TRACT; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA, MUCINOUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863563244     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.085688     Document Type: Review

References (69)

1. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4. (Pubitemid 38018236)
2. Köbel M, Kalloger SE, Huntsman DG, et al; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29:203-11.
3. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005;24:4-25. (Pubitemid 40066450)
4. McCluggage WG. My approach to and thoughts on typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63. (Pubitemid 351218874)
5. Lerwill MF, Young RH. Mucinous tumours of the ovary. Diagn Histopathol 2008;14:366-87.
6. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005;47:231-47. (Pubitemid 41243261)
7. Lee KR, Young RH. The distinction between primary and secondary mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003;27:281-92. (Pubitemid 36245793)
8. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovary: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27:985-93. (Pubitemid 36763545)
9. Tabrizi AD, Kalloger SE, Kobel M, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 2010;29:99-107.
10. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol 2010;29:108-12.
11. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009;9:433.
12. Lewis MR, Deavers MT, Silva EG, et al. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol 2006;30:177-84. (Pubitemid 43740186)
13. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000;53:558-60.
14. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 2002;46:309-26. (Pubitemid 34595581)
15. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005;22:3-32. (Pubitemid 43163177)
16. McCluggage WG. Immunohistochemical markers as a diagnostic aid in ovarian pathology. Diagn Histopathol 2008;14:335-51.
17. Berezowski K, Stasny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996;9:1040-4.
18. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-85. (Pubitemid 35416704)
19. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colon and breast origin. Comparison between a statistical and intuitive approach. J Clin Pathol 1999;52:283-90. (Pubitemid 29161492)
20. Raspollini MR, Amunni G, Villannucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma. Appl Immunohistochem Mol Morphol 2004;12:127-31. (Pubitemid 38788761)
21. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10. (Pubitemid 36245795)
22. Groisman GM, Meir A, Sabo E. The value of cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol 2003;23:52-7. (Pubitemid 38018238)
23. Tornillo L, Moch H, Diener PA, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol 2004;57:641-3. (Pubitemid 38725768)
24. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19:1421-8. (Pubitemid 44624160)
25. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology 2008;53:156-65. (Pubitemid 352032773)
26. Wani Y, Notochara K, Saegusa M, et al. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation. Hum Pathol 2008;39:1072-9.
27. Kelly P, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 2010;63:169-73.
28. Zhang PJ, Shah M, Spiegel GW, et al. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol 2003;11:306-10. (Pubitemid 37522680)
29. Saad RS, Silverman JF, Khalifa MA, et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2009;17:196-201.
30. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003;42:137-40. (Pubitemid 36237845)
31. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with b-catenin. Histopathology 2003;43:151-6.
32. Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, et al. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma form gastrointestinal cancers that commonly metastasise to the ovary. J Clin Pathol 2007;60:622-6. (Pubitemid 46975215)
33. Ciocca V, Bombonati A, Palazzo JP, et al. Guanyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology 2009;55:182-8.
34. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005;18:19-25. (Pubitemid 40128090)
35. Albarracin CT, Jafri J, Montag AG, et al. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000;31:672-7. (Pubitemid 30445469)
36. Okamoto T, Matsumura N, Mandai M, et al. Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Mod Pathol 2011;24:267-76.
37. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006;94:904-13.
38. Geyer GT, Lopez-Garcia MA, Sanchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009;33:1157-63.
39. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007;31:854-69. (Pubitemid 47165138)
40. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 2003;27:650-7. (Pubitemid 36514475)
41. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 1995;26:509-24.
42. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995;19:1390-408.
43. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997;16:1-9. (Pubitemid 27199578)
44. Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol 1995;8:573-6.
45. O'Connell JT, Hacker CM, Barsky SH. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol 2002;15:958-72.
46. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997;21:1144-55. (Pubitemid 27422313)
47. Young RH, Scully RE. Ovarian metastases from carcinoma of the gallbladder and extrahepatic bile ducts simulating primary tumors of the ovary: a report of six cases. Int J Gynecol Pathol 1990;9:60-72. (Pubitemid 20067457)
48. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal and pancreaticobiliary epithelial cells. Cancer 1992;69:2131-42.
49. Tempero M, Takasaki H, Uchida E, et al. Co-expression of CA19.9, DU-PAN-2, CA125 and TAG-72 in pancreatic adenocarcinoma. Am J Surg Pathol 1989;13(Suppl 1):89-95. (Pubitemid 19142066)
50. Han L, Pansare V, Al-Abbadi M, et al. Combination of MUC5AC and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol 2010;38:333-6.
51. Miller K, Millar J, McCluggage WG. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of intestinal type. Am J Surg Pathol (In press).
52. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001;116:246-52. (Pubitemid 33044330)
53. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4 and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous carcinomas: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391-400.
54. Tascilar M, Offerhaus GJ, Altink R, et al. Immunohistochemical labelling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens from the pancreas and bile duct. Am J Clin Pathol 2001;116:831-7. (Pubitemid 33108153)
55. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001;19:1332-41. (Pubitemid 32267045)
56. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30. (Pubitemid 26170688)
57. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labelling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43. (Pubitemid 30644436)
58. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their use in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 2005;24:67-72. (Pubitemid 40066455)
59. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 2008;32:1835-53.
60. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol 2005;29:281-94. (Pubitemid 40321963)
61. Chang MC, Nevadunsky NS, Viswanathan AN, et al. Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long term survival. Int J Gynecol Pathol 2010;29:88-92.
62. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15. (Pubitemid 44357144)
63. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 2007;31:653-63. (Pubitemid 46684203)
64. Wentzensen N, Du Bois A, Kommoss S, et al. No metastatic cervical adenocarcinomas in a series of p16INK4A positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group. Int J Gynecol Pathol 2007;27:18-23. (Pubitemid 351627967)
65. Houghton O, Jamison J, Wilson R, et al. p16 immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology 2010;57:342-50.
66. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004;28:1311-18. (Pubitemid 39336369)
67. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105. (Pubitemid 43250984)
68. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006;25:83-9. (Pubitemid 44638341)
69. Yasunaga M, Ohishi Y, Oda Y, et al. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 2009;40:965-74.